- Home
- RDIB vs GNLX Comparison
RDIB vs GNLX Comparison
Compare RDIB & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- GNLX
- Stock Information
- Founded
- RDIB 1937
- GNLX 2001
- Country
- RDIB United States
- GNLX United States
- Employees
- RDIB N/A
- GNLX N/A
- Industry
- RDIB Movies/Entertainment
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- RDIB Consumer Discretionary
- GNLX Health Care
- Exchange
- RDIB Nasdaq
- GNLX Nasdaq
- Market Cap
- RDIB 140.2M
- GNLX 112.5M
- IPO Year
- RDIB N/A
- GNLX 2023
- Fundamental
- Price
- RDIB $10.20
- GNLX $3.44
- Analyst Decision
- RDIB
- GNLX Strong Buy
- Analyst Count
- RDIB 0
- GNLX 4
- Target Price
- RDIB N/A
- GNLX $17.75
- AVG Volume (30 Days)
- RDIB 11.4K
- GNLX 153.5K
- Earning Date
- RDIB 08-13-2025
- GNLX 08-13-2025
- Dividend Yield
- RDIB N/A
- GNLX N/A
- EPS Growth
- RDIB N/A
- GNLX N/A
- EPS
- RDIB N/A
- GNLX N/A
- Revenue
- RDIB $205,644,000.00
- GNLX N/A
- Revenue This Year
- RDIB $7.47
- GNLX N/A
- Revenue Next Year
- RDIB $13.22
- GNLX N/A
- P/E Ratio
- RDIB N/A
- GNLX N/A
- Revenue Growth
- RDIB N/A
- GNLX N/A
- 52 Week Low
- RDIB $5.78
- GNLX $1.60
- 52 Week High
- RDIB $21.34
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- RDIB 50.27
- GNLX 65.71
- Support Level
- RDIB $9.30
- GNLX $2.80
- Resistance Level
- RDIB $11.82
- GNLX $3.61
- Average True Range (ATR)
- RDIB 0.68
- GNLX 0.22
- MACD
- RDIB 0.06
- GNLX 0.05
- Stochastic Oscillator
- RDIB 44.38
- GNLX 80.23
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.